General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
The company generated ₹102 cr in revenue for FY26, an increase from ₹100 cr the prior year. However, operating profit swung into red territory at -₹24 cr, driven by a -24% operating margin. Net profit hit -₹29 cr (loss).
A rights issue in May 2026 raised ₹70 cr at ₹40 per share (155% subscribed). Shares issued rose from 2.8 cr to 9.3 cr, instantly diluting the equity base by 230%.
Total debt stands at ₹113 cr against a ₹1,067 cr market cap. Interest coverage has collapsed into negative territory. The balance sheet now shows ₹278 cr in total liabilities against ₹278 cr in assets — a 1:1 levering with minimal buffer.
Inventories are ₹56 cr; receivables ₹31 cr; cash ₹5 cr. The company is burning cash to sustain operations and expanding headcount and asset base.
What happens when a CRDMO with zero near-term profitability runs out of fresh capital?
2 — Introduction
Innovassynth Technologies (ITIL) is a chemistry-focused contract research, development, and manufacturing organization (CRDMO) incorporated in 2008 and positioned in the specialty chemicals and pharmaceutical intermediates space.
The company operates across three verticals: pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It serves global life sciences and advanced materials customers with custom synthesis, process development, scale-up, and commercial manufacturing.
In 2022, the business transitioned to profitability with a ₹22 cr net profit, backed by ₹203 cr revenue. Since then, margins have eroded and losses have resumed. FY24 and FY25 posted net losses of ₹1 cr and ₹1 cr respectively before ballooning to -₹29 cr in FY26.
A postal ballot in March 2026 approved increased borrowing limits. The subsequent rights issue was meant to address this burn.
The company’s Khopoli facility has been augmented with capex aimed at capacity expansion for oligonucleotide and specialty chemical manufacturing.
3 — Business Model: WTF Do They Even Do?
Innovassynth is a CRDMO — a middleman between pharmaceutical discovery firms and final manufacturing. It doesn’t invent drugs. It makes the intermediate chemicals that go into them, or builds the building blocks (nucleosides, amidites) that RNA/DNA therapy companies need.
The oligonucleotide vertical is the crown jewel: nucleosides and amidites are the monomeric units of DNA and RNA, used in mRNA vaccines, gene therapy, and RNA therapeutics. As that market expands (it has), demand for oligos compounds.
The specialty chemicals vertical serves polyolefins (plastics), organometallic catalysts (used in fine chemistry), and semiconductor materials. This is a low-margin, high-volume game — competitive, price-sensitive, and vulnerable to cost shocks.
The pharmaceutical intermediates vertical is the legacy play: custom synthesis for drug discovery and manufacturing. Margins are thin, customers are global (so FX risk bites), and capacity utilization is the bottleneck.
Revenue mix in FY25 was 99% product sales, 1% other income. That makes the business a one-trick: if synthesis demand drops or margins compress, there’s no buffer.
The CRDMO model is asset-heavy and capital-hungry. Khopoli is now saddled with ₹130 cr in net block (fixed assets), requiring continuous investment and debt service.
4 — Financials Overview
Figures are consolidated, in ₹ crore.
Metric
FY26
FY25
FY24
YoY Change
Revenue
102.35
102.35
102.35
—
EBITDA
-16
—
—
—
Operating Profit
-24
—
—
—
PAT (Net Profit)
-29
-1
-1
-2,800%
EPS (Annualised)
-3.10
—
—
—
FY26 Quarterly Trajectory:
Q1 (Jun 25): Revenue ₹0, PAT ₹0 (no data reported or minimal operations).
Q2 (Sep 25): Revenue ₹17 cr, PAT -₹14 cr.
Q3 (Dec 25): Revenue ₹22 cr, PAT -₹8 cr.
Q4 (Mar 26): Revenue ₹51 cr, PAT ₹12 cr.
The company went from cumulative losses of ₹22 cr in the first three quarters to a sole profitable quarter in Q4. That single quarter of ₹12 cr profit offset most of the damage, but not all. The full-year loss of ₹29 cr includes the rights issue proceeds (which inflate the balance sheet) but not the dilution’s ongoing drag on earnings per share.
Q4 saw a 23% OPM — a rare bright spot. Q2 posted -64% OPM. Volatility is extreme.
